Chemoprophylaxis and intermittent treatment for preventing malaria in children

Martin M Meremikwu; Aika AA Omari; Paul Garner

doi:10.1002/14651858.CD003756.pub2

Scolaris Content Display Scolaris Content Display

Contenido relacionado

Ir a:

Revisiones y protocolos relacionados
Guías
Temas

Revisiones y protocolos relacionados

Topics

Temas

Analysis 1.1

Comparison 1 Antimalarial versus placebo: main analysis, Outcome 1 Clinical malaria.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Analysis 1.2

Comparison 1 Antimalarial versus placebo: main analysis, Outcome 2 Severe anaemia.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Analysis 1.3

Comparison 1 Antimalarial versus placebo: main analysis, Outcome 3 Death from any cause.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Analysis 1.4

Comparison 1 Antimalarial versus placebo: main analysis, Outcome 4 Hospital admission for any cause.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Analysis 1.5

Comparison 1 Antimalarial versus placebo: main analysis, Outcome 5 Parasitaemia.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Analysis 1.6

Comparison 1 Antimalarial versus placebo: main analysis, Outcome 6 Enlarged spleen.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Analysis 1.7

Comparison 1 Antimalarial versus placebo: main analysis, Outcome 7 Mean haematocrit.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Analysis 1.8

Comparison 1 Antimalarial versus placebo: main analysis, Outcome 8 Adverse events.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Analysis 2.1

Comparison 2 Antimalarial versus placebo: by drug group, Outcome 1 Clinical malaria.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Analysis 2.2

Comparison 2 Antimalarial versus placebo: by drug group, Outcome 2 Severe anaemia.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Analysis 3.1

Comparison 3 Antimalarial versus placebo: by seasonality, Outcome 1 Clinical malaria.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Analysis 3.2

Comparison 3 Antimalarial versus placebo: by seasonality, Outcome 2 Severe anaemia.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Analysis 4.1

Comparison 4 Intermittent treatment versus placebo: by presence of anaemia, Outcome 1 Clinical malaria.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Analysis 4.2

Comparison 4 Intermittent treatment versus placebo: by presence of anaemia, Outcome 2 Severe anaemia.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Analysis 5.1

Comparison 5 Antimalarial versus placebo: adequately concealed trials, Outcome 1 Clinical malaria.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Analysis 5.2

Comparison 5 Antimalarial versus placebo: adequately concealed trials, Outcome 2 Severe anaemia.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Analysis 5.3

Comparison 5 Antimalarial versus placebo: adequately concealed trials, Outcome 3 Death from any cause.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Analysis 6.1

Comparison 6 Antimalarial versus placebo: excluding cluster‐randomized controlled trials, Outcome 1 Severe anaemia.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Analysis 6.2

Comparison 6 Antimalarial versus placebo: excluding cluster‐randomized controlled trials, Outcome 2 Death from any cause.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Analysis 6.3

Comparison 6 Antimalarial versus placebo: excluding cluster‐randomized controlled trials, Outcome 3 Parasitaemia.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Analysis 7.1

Comparison 7 Antimalarial versus placebo: impact after stopping intervention, Outcome 1 Clinical malaria.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Analysis 7.2

Comparison 7 Antimalarial versus placebo: impact after stopping intervention, Outcome 2 Severe anaemia.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Analysis 7.3

Comparison 7 Antimalarial versus placebo: impact after stopping intervention, Outcome 3 Death from any cause (within 2 years of stopping intervention).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Analysis 7.4

Comparison 7 Antimalarial versus placebo: impact after stopping intervention, Outcome 4 Parasitaemia.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Analysis 7.5

Comparison 7 Antimalarial versus placebo: impact after stopping intervention, Outcome 5 Enlarged spleen.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Analysis 7.6

Comparison 7 Antimalarial versus placebo: impact after stopping intervention, Outcome 6 Mean haematocrit.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Analysis 7.7

Comparison 7 Antimalarial versus placebo: impact after stopping intervention, Outcome 7 Protective measles antibody titres.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Table 1. Detailed search strategies

Search set	CIDG SR*	CENTRAL	MEDLINE**	EMBASE**	LILACS**
1	malaria	malaria	MALARIA	MALARIA	malaria
2	prophylaxis	prophylaxis	malaria	malaria	prophylaxis
3	intermittent treatment	intermittent treatment	1 or 2	1 or 2	prevention
4	‐	presumptive treatment	prophylaxis	prophylaxis	2 or 3
5	‐	2 or 3 or 4	chemoprophylaxis	chemoprophylaxis	1 and 4
6	‐	1 and 5	prevention	prevention	‐
7	‐	‐	intermittent treatment	intermittent treatment	‐
8	‐	‐	presumptive treatment	presumptive treatment	‐
9	‐	‐	4 or 5 or 6 or 7 or 8	4 or 5 or 6 or 7 or 8	‐
10	‐	‐	3 and 9	3 and 9	‐
	*Cochrane Infectious Diseases Group Specialized Register		**Search terms used in combination with the search strategy for retrieving trials developed by The Cochrane Collaboration (Higgins 2005); Upper case: MeSH or EMTREE heading; Lower case: free text term

Table 1. Detailed search strategies

Ir a la tabla de la revisión

Table 2. Types of intervention

Trial	No. arms	Intervention	Iron or folic acid	ITNs*
Alonso 1993	1	Pyrimethamine‐dapsone	No	Yes
	2	Placebo	No	Yes
Bradley‐Moore 1985	1	Chloroquine	No	No
	2	Pyrimethamine	No	No
	3	Placebo	No	No
David 1997	1	Pyrimethamine‐dapsone	No	No
	2	Placebo	No	No
Desai 2003	1	Sulfadoxine‐pyrimethamine	No	Yes**
	2	‐‐	Iron	Yes**
	3	Sulfadoxine‐pyrimethamine	Iron	Yes**
	4	Placebo	No	Yes**
Greenwood 1988	1	Pyrimethamine‐dapsone	No	No
	2	Placebo	No	No
Greenwood 1989	1	Pyrimethamine‐dapsone	Folic acid	No
	2	Pyrimethamine‐dapsone	No	No
	3	Chlorproguanil	Folic acid	No
	4	Chlorproguanil	No	No
	5	Placebo	Folic acid	No
	6	Placebo	No	No
Greenwood 1995	1	Pyrimethamine‐dapsone	No	No
	2	Placebo	No	No
Hogh 1993	1	Chloroquine	No	No
	2	Placebo	No	No
Lemnge 1997	1	Pyrimethamine‐dapsone	No	No
	2	Placebo	No	No
Massaga 2003	1	Amodiaquine	Iron	No
	2	Amodiaquine	No	No
	3	Placebo	Iron	No
	4	Placebo	No	No
Menendez 1997	1	Pyrimethamine‐dapsone	No	No
	2	Pyrimethamine‐dapsone	Iron	No
	3	Placebo	Iron	No
	4	Placebo	No	No
Menon 1990	1	Pyrimethamine‐dapsone	No	No
	2	Placebo	No	No
Otoo 1988	1	Pyrimethamine‐dapsone	No	No
	2	Placebo	No	No
Oyediran 1993	1	Chloroquine	No	No
	2	Pyrimethamine	No	No
	3	Placebo	No	No
Schellenberg 2001	1	Sulfadoxine‐pyrimethamine	No	No
	2	Placebo	No	No
Schellenberg 2005	1	Sulfadoxine‐pyrimethamine	No	No
	2	Placebo	No	No
Tomashek 2001	1	Sulfadoxine‐pyrimethamine plus vitamins A and C	Iron, folic acid	No
	2	Sulfadoxine‐pyrimethamine	Iron, folic acid	No
	3	Placebo	Iron, folic acid	No
Verhoef 2002	1	Sulfadoxine‐pyrimethamine	No	No
	2	‐‐	Iron	No
	3	Sulfadoxine‐pyrimethamine	Iron	No
	4	Placebo	No	No
Wolde 1994	1	Chloroquine	No	No
	2	Placebo	No	No
Footnotes ITNs: insecticide‐treated nets *ITNs not given to participants but reported that they benefited from their "area‐wide deployment"

Table 2. Types of intervention

Ir a la tabla de la revisión

Table 3. Methodological quality of included trials

Trial	Sequence*	Concealment*	Blinding	Primary outcome (n)	Number at follow up	Percentage loss
Alonso 1993	Unclear	Unclear	Double	Clinical malaria (1898 participants)	NA	NA
Bradley‐Moore 1985	Inadequate (alternate allocation)	Unclear	Unclear	Clinical malaria, severe anaemia (449 participants)	NA	NA
David 1997	Unclear	Unclear	Unclear	‐	NA	NA
Desai 2003	Adequate (block randomization)	Adequate (identical and centrally coded drugs and placebo)	Double	Clinical malaria (428 participants)	468	14% (inadequate)
Greenwood 1988	Unclear	Unclear	Double	Clinical malaria, severe anaemia (2718 participants)	NA	NA
Greenwood 1989	Unclear	Unclear	Double	Clinical malaria (560 participants)	NA	NA
Greenwood 1995**	Unclear	Unclear	Double	‐	NA	19% to 22% (inadequate)
Hogh 1993	Unclear	Unclear	Unclear	‐	NA	NA
Lemnge 1997	Unclear	Adequate (identical and centrally coded drugs and placebo)	Double	‐	234	6% (adequate)
Massaga 2003	Adequate (computer‐generated random numbers)	Adequate (identical and centrally coded drugs and placebo)	Double	Clinical malaria (291 participants)	231	21% (inadequate)
Menendez 1997	Adequate (block randomization)	Adequate (identical and centrally coded drugs and placebo)	Double	Severe anaemia (832 participants)	NA	7% (adequate)
Menon 1990	Unclear	Unclear	Double	‐	NA	NA
Otoo 1988a**	Unclear	Unclear	Double	Clinical malaria (95 participants)	NA	16% (inadequate)
Oyediran 1993	Inadequate (alternate allocation)	Unclear	Unclear	Clinical malaria, severe anaemia (696 participants)	NA	NA
Schellenberg 2001	Adequate (computer‐generated)	Adequate (sealed, opaque envelopes and identical, centrally coded drugs and placebo)	Double	Clinical malaria, severe anaemia (701 participants)	677	3% (adequate)
Schellenberg 2005	Adequate (computer‐generated)	Adequate (sealed, opaque envelopes and identical, centrally coded drugs and placebo)	Double	Clinical malaria, severe anaemia, protective antibody titres against measles (555)	555	NA
Tomashek 2001	Adequate (computer‐generated)	Unclear	Double	Anaemia prevalence (238 participants)	215	9.7% (adequate)
Verhoef 2002	Adequate (block randomization)	Adequate (identical and centrally coded drugs and placebo)	Double	Clinical malaria (328 participants)	309	6% (adequate)
Wolde 1994	Unclear	Unclear	Unclear	Clinical malaria (1005 participants)	997	9% (adequate)
Footnotes Generation of allocation sequence; concealment of allocation Late impact trials NA: not available Footnotes Generation of allocation sequence; concealment of allocation **Late impact trials NA: not available

Table 3. Methodological quality of included trials

Ir a la tabla de la revisión

Table 4. Adverse event information not appropriate for meta‐analysis

Trial	Method to detect AE*	Results
Greenwood 1988	White cell count in randomly selected subset of 68 participants on Maloprim (pyrimethamine‐dapsone) and 78 on placebo	Almost identical mean white cell count for the Maloprim group (9.3 x 10^L) and placebo group (9.6 x 10^/L) Lowest white cell count recorded was 2.8 x 10^/L (study group not indicated) No severe adverse event reported Almost identical mean white cell count for the Maloprim group (9.3 x 10^L) and placebo group (9.6 x 10^/L) Lowest white cell count recorded was 2.8 x 10^/L (study group not indicated) No severe adverse event reported
Greenwood 1989	Clinical assessment and white cell count White cell counts on alternate participants in 1983 and attempted on all participants in 1984	White cell count and clinical assessment showed no features suggestive of agranulocytosis in treatment (Maloprim) and placebo groups Results from Fuller 1988 (reporting on the Greenwood 1989 trial): "Mean WBC [white blood cell] count of children and the distribution of WBC counts were very similar in children who received Maloprim, chlorproguanil and placebo during each survey."
Lemnge 1997	White cell count; weight and height	Results available for 242 participants: 65 placebo, 58 iron, 60 amodiaquine, and 59 amodiaquine and iron "No serious side effect was observed." "Reduction in … neutrophil counts, in children with normal baseline values, were sometimes seen but these were temporary." "No pronounced weight loss was observed in any child."
Massaga 2003	Total and differential white cell counts	"No clinical adverse effects such as sore throat or agranulocytosis were reported or observed during the study." "No significant difference in mean leucocyte counts between the groups."
Footnotes AE: adverse event

Table 4. Adverse event information not appropriate for meta‐analysis

Ir a la tabla de la revisión

Comparison 1. Antimalarial versus placebo: main analysis

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Clinical malaria Show forest plot	8	4051	Risk Ratio (M‐H, Random, 95% CI)	0.52 [0.35, 0.77]

1.1 Prophylaxis	4	2806	Risk Ratio (M‐H, Random, 95% CI)	0.57 [0.33, 1.00]
1.2 Intermittent treatment	4	1245	Risk Ratio (M‐H, Random, 95% CI)	0.48 [0.33, 0.71]
2 Severe anaemia Show forest plot	8	2727	Risk Ratio (M‐H, Fixed, 95% CI)	0.54 [0.42, 0.68]

2.1 Prophylaxis	4	1509	Risk Ratio (M‐H, Fixed, 95% CI)	0.51 [0.37, 0.69]
2.2 Intermittent treatment	4	1218	Risk Ratio (M‐H, Fixed, 95% CI)	0.58 [0.40, 0.84]
3 Death from any cause Show forest plot	11	7929	Risk Ratio (M‐H, Fixed, 95% CI)	0.82 [0.65, 1.04]

3.1 Prophylaxis	7	6685	Risk Ratio (M‐H, Fixed, 95% CI)	0.80 [0.63, 1.03]
3.2 Intermittent treatment	4	1244	Risk Ratio (M‐H, Fixed, 95% CI)	0.98 [0.49, 1.99]
4 Hospital admission for any cause Show forest plot	3	1149	Risk Ratio (M‐H, Fixed, 95% CI)	0.60 [0.52, 0.68]

4.1 Prophylaxis	1	303	Risk Ratio (M‐H, Fixed, 95% CI)	0.49 [0.40, 0.60]
4.2 Intermittent treatment	2	846	Risk Ratio (M‐H, Fixed, 95% CI)	0.66 [0.56, 0.79]
5 Parasitaemia Show forest plot	6	1785	Risk Ratio (M‐H, Random, 95% CI)	0.37 [0.17, 0.79]

5.1 Prophylaxis	4	1426	Risk Ratio (M‐H, Random, 95% CI)	0.24 [0.13, 0.45]
5.2 Intermittent treatment	2	359	Risk Ratio (M‐H, Random, 95% CI)	0.85 [0.64, 1.13]
6 Enlarged spleen Show forest plot	4	1589	Risk Ratio (M‐H, Random, 95% CI)	0.28 [0.14, 0.56]

6.1 Prophylaxis	4	1589	Risk Ratio (M‐H, Random, 95% CI)	0.28 [0.14, 0.56]
7 Mean haematocrit Show forest plot	3	794	Mean Difference (IV, Fixed, 95% CI)	2.12 [1.47, 2.77]

7.1 Prophylaxis	3	794	Mean Difference (IV, Fixed, 95% CI)	2.12 [1.47, 2.77]
8 Adverse events Show forest plot	2		Risk Ratio (M‐H, Fixed, 95% CI)	Subtotals only

8.1 Vomiting (prophylaxis)	1	415	Risk Ratio (M‐H, Fixed, 95% CI)	2.99 [0.31, 28.47]
8.2 Hyperpigmented macules (prophylaxis)	1	886	Risk Ratio (M‐H, Fixed, 95% CI)	67.08 [4.12, 1092.11]

Comparison 1. Antimalarial versus placebo: main analysis

Ir a la tabla de la revisión

Comparison 2. Antimalarial versus placebo: by drug group

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Clinical malaria Show forest plot	8	4051	Risk Ratio (M‐H, Random, 95% CI)	0.52 [0.35, 0.77]

1.1 Pyrimethamine‐dapsone	1	724	Risk Ratio (M‐H, Random, 95% CI)	0.16 [0.02, 1.34]
1.2 Chloroquine	3	2082	Risk Ratio (M‐H, Random, 95% CI)	0.62 [0.36, 1.08]
1.3 Sulfadoxine‐pyrimethamine (intermittent treatment)	3	1100	Risk Ratio (M‐H, Random, 95% CI)	0.56 [0.41, 0.78]
1.5 Amodiaquine (intermittent treatment)	1	145	Risk Ratio (M‐H, Random, 95% CI)	0.29 [0.19, 0.45]
2 Severe anaemia Show forest plot	8	2727	Risk Ratio (M‐H, Fixed, 95% CI)	0.54 [0.42, 0.68]

2.1 Pyrimethamine‐dapsone	2	656	Risk Ratio (M‐H, Fixed, 95% CI)	0.46 [0.33, 0.64]
2.2 Chloroquine	2	853	Risk Ratio (M‐H, Fixed, 95% CI)	1.15 [0.39, 3.40]
2.4 Sulfadoxine‐pyrimethamine (intermittent treatment)	3	1073	Risk Ratio (M‐H, Fixed, 95% CI)	0.73 [0.46, 1.15]
2.5 Amodiaquine (intermittent treatment)	1	145	Risk Ratio (M‐H, Fixed, 95% CI)	0.34 [0.17, 0.68]

Comparison 2. Antimalarial versus placebo: by drug group

Ir a la tabla de la revisión

Comparison 3. Antimalarial versus placebo: by seasonality

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Clinical malaria Show forest plot	8	4053	Risk Ratio (M‐H, Random, 95% CI)	0.52 [0.35, 0.77]

1.1 Seasonal	3	1893	Risk Ratio (M‐H, Random, 95% CI)	0.73 [0.43, 1.24]
1.2 Perennial	5	2160	Risk Ratio (M‐H, Random, 95% CI)	0.47 [0.31, 0.71]
2 Severe anaemia Show forest plot	8	2727	Risk Ratio (M‐H, Fixed, 95% CI)	0.54 [0.42, 0.68]

2.1 Seasonal	1	241	Risk Ratio (M‐H, Fixed, 95% CI)	0.13 [0.01, 2.43]
2.2 Perennial	7	2486	Risk Ratio (M‐H, Fixed, 95% CI)	0.55 [0.43, 0.70]

Comparison 3. Antimalarial versus placebo: by seasonality

Ir a la tabla de la revisión

Comparison 4. Intermittent treatment versus placebo: by presence of anaemia

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Clinical malaria Show forest plot	4		Risk Ratio (M‐H, Random, 95% CI)	Subtotals only

1.1 All participants	2	846	Risk Ratio (M‐H, Random, 95% CI)	0.37 [0.25, 0.55]
1.2 Only anaemic children	2	399	Risk Ratio (M‐H, Random, 95% CI)	0.69 [0.48, 0.98]
2 Severe anaemia Show forest plot	4		Risk Ratio (M‐H, Random, 95% CI)	Subtotals only

2.1 All participants	2	846	Risk Ratio (M‐H, Random, 95% CI)	0.42 [0.27, 0.67]
2.2 Only anaemic children	2	372	Risk Ratio (M‐H, Random, 95% CI)	1.31 [0.63, 2.72]

Comparison 4. Intermittent treatment versus placebo: by presence of anaemia

Ir a la tabla de la revisión

Comparison 5. Antimalarial versus placebo: adequately concealed trials

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Clinical malaria Show forest plot	4	1245	Risk Ratio (M‐H, Random, 95% CI)	0.48 [0.33, 0.71]

1.1 Prophylaxis	0	0	Risk Ratio (M‐H, Random, 95% CI)	0.0 [0.0, 0.0]
1.2 Intermittent treatment	4	1245	Risk Ratio (M‐H, Random, 95% CI)	0.48 [0.33, 0.71]
2 Severe anaemia Show forest plot	4	1470	Risk Ratio (M‐H, Fixed, 95% CI)	0.50 [0.39, 0.64]

2.1 Prophylaxis	1	415	Risk Ratio (M‐H, Fixed, 95% CI)	0.48 [0.34, 0.67]
2.2 Intermittent treatment	3	1055	Risk Ratio (M‐H, Fixed, 95% CI)	0.52 [0.35, 0.77]
3 Death from any cause Show forest plot	4	1495	Risk Ratio (M‐H, Fixed, 95% CI)	0.64 [0.34, 1.22]

3.1 Prophylaxis	1	415	Risk Ratio (M‐H, Fixed, 95% CI)	0.20 [0.04, 0.90]
3.2 Intermittent treatment	3	1080	Risk Ratio (M‐H, Fixed, 95% CI)	0.98 [0.46, 2.09]

Comparison 5. Antimalarial versus placebo: adequately concealed trials

Ir a la tabla de la revisión

Comparison 6. Antimalarial versus placebo: excluding cluster‐randomized controlled trials

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Severe anaemia Show forest plot	7	2486	Risk Ratio (M‐H, Fixed, 95% CI)	0.55 [0.43, 0.70]

1.1 Prophylaxis	3	1268	Risk Ratio (M‐H, Fixed, 95% CI)	0.53 [0.38, 0.72]
1.2 Intermittent treatment	4	1218	Risk Ratio (M‐H, Fixed, 95% CI)	0.58 [0.40, 0.84]
2 Death from any cause Show forest plot	7	4247	Risk Ratio (M‐H, Fixed, 95% CI)	1.02 [0.76, 1.39]

2.1 Prophylaxis	4	3166	Risk Ratio (M‐H, Fixed, 95% CI)	1.03 [0.74, 1.44]
2.2 Intermittent treatment	3	1081	Risk Ratio (M‐H, Fixed, 95% CI)	0.98 [0.46, 2.09]
3 Parasitaemia Show forest plot	4	1194	Risk Ratio (M‐H, Random, 95% CI)	0.46 [0.17, 1.26]

3.1 Prophylaxis	2	835	Risk Ratio (M‐H, Random, 95% CI)	0.26 [0.06, 1.21]
3.2 Intermittent treatment	2	359	Risk Ratio (M‐H, Random, 95% CI)	0.85 [0.64, 1.13]

Comparison 6. Antimalarial versus placebo: excluding cluster‐randomized controlled trials

Ir a la tabla de la revisión

Comparison 7. Antimalarial versus placebo: impact after stopping intervention

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Clinical malaria Show forest plot	2		Risk Ratio (M‐H, Fixed, 95% CI)	Totals not selected

1.1 Prophylaxis	1		Risk Ratio (M‐H, Fixed, 95% CI)	0.0 [0.0, 0.0]
1.2 Intermittent treatment	1		Risk Ratio (M‐H, Fixed, 95% CI)	0.0 [0.0, 0.0]
2 Severe anaemia Show forest plot	1		Risk Ratio (M‐H, Fixed, 95% CI)	Totals not selected

3 Death from any cause (within 2 years of stopping intervention) Show forest plot	1		Risk Ratio (M‐H, Fixed, 95% CI)	Subtotals only

4 Parasitaemia Show forest plot	2		Risk Ratio (M‐H, Fixed, 95% CI)	Subtotals only

5 Enlarged spleen Show forest plot	2	305	Risk Ratio (M‐H, Fixed, 95% CI)	0.96 [0.60, 1.52]

6 Mean haematocrit Show forest plot	1		Mean Difference (IV, Fixed, 95% CI)	Subtotals only

7 Protective measles antibody titres Show forest plot	1		Risk Ratio (M‐H, Fixed, 95% CI)	Subtotals only

Comparison 7. Antimalarial versus placebo: impact after stopping intervention

Ir a la tabla de la revisión

The Cochrane Library

Scolaris Language Selector Scolaris Language Selector

Idioma de la Revisión Cochrane

Idioma de la web

Scolaris Content Language Banner Portlet Scolaris Content Language Banner Portlet